The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PTN | -66.69% | -98.85% | -59.08% | -100% |
| S&P | +14.39% | +76.41% | +12.02% | +1,384% |
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
A high-profile analyst questioned the company's recent FDA approval.
Investors were hit with a barrage of news today. Here's a look at the key details that investors need to know.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.85M | 0.0% |
| Gross Profit | -$52.99K | -129.4% |
| Gross Margin | 51.45% | 0.0% |
| Market Cap | $7.71M | -55.9% |
| Market Cap / Employee | $265.70K | 0.0% |
| Employees | 29 | -3.3% |
| Net Income | $4.68M | 159.8% |
| EBITDA | $4.68M | 161.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.27M | -46.6% |
| Accounts Receivable | $6.89M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $132.45K | -60.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -79.90% | 361.4% |
| Return On Invested Capital | -11011.68% | 78.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,619.38K | 76.9% |
| Operating Free Cash Flow | -$1,619.38K | 76.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -4.08 | -2.61 | -1.36 | -1.54 | -32.28% |
| Price to Sales | 7.44 | 65.44 | 43.88 | 0.98 | -86.56% |
| Price to Tangible Book Value | -141.16 | -107.13 | -31.30 | -1.54 | -99.98% |
| Enterprise Value to EBITDA | -4.01 | -2.53 | -0.90 | 1.62 | -177.51% |
| Return on Equity | -588.7% | -269476.6% | - | ||
| Total Debt | $357.74K | $262.22K | $163.78K | $132.45K | -71.85% |
No podcast episodes available.
PTN earnings call for the period ending March 31, 2020.
PTN earnings call for the period ending December 31, 2019.
PTN earnings call for the period ending September 30, 2019.
PTN earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
